Three-dimensional ultrasound integrating nomogram and the blood flow image for prostate cancer diagnosis and biopsy : A retrospective study
Copyright © 2022 Chen, Niu, Chen, Liu, Guo, Yao, Li, Luo, Li and Tang..
Backgrounds: Prostate cancer (PCa) is the second most common male cancer in the world and based on its high prevalence and overwhelming effect on patients, more precise diagnostic and therapeutic methods are essential research topics. As such, this study aims to evaluate the value of three-dimensional transrectal ultrasound (3D-TRUS) in the detection, diagnosis and biopsy of PCa, and to provide a basis for clinical practice of PCa.
Methods: Retrospective analysis and comparison of a total of 401 male patients who underwent prostate TRUS in our hospital from 2019 to 2020 were conducted, with all patients having prostate biopsy. Nomogram was used to estimate the probability of different ultrasound signs in diagnosing prostate cancer. The ROC curve was used to estimate the screening and diagnosis rates of 3D-TRUS, MRI and TRUS for prostate cancer.
Results: A total of 401 patients were randomly divided into two groups according to different methods of prostate ultrasonography, namely the TRUS group (251 patients) and the 3D-TRUS group (150 patients). Of these cases, 111 patients in 3D-TRUS group underwent MRI scan. The nomogram further determined the value of 3D-TRUS for prostate cancer. The ROC AUC of prostate cancer detected by TRUS, MRI and 3D-TRUS was 0.5580, 0.6216 and 0.6267 respectively. Biopsy complications were lower in 3D-TRUS group than TRUS group, which was statistically significant (P<0.005).
Conclusions: The accuracy of 3D-TRUS was higher in diagnosis and biopsy of prostate cancer. Meanwhile, the positive rate of biopsy could be improved under direct visualization of 3D-TRUS, and the complications could be decreased markedly. Therefore, 3D-TRUS was of high clinical value in diagnosis and biopsy of prostate cancer.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Frontiers in oncology - 12(2022) vom: 22., Seite 994296 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chen, Dong [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biopsy |
|---|
| Anmerkungen: |
Date Revised 18.11.2022 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3389/fonc.2022.994296 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM349004803 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM349004803 | ||
| 003 | DE-627 | ||
| 005 | 20231226205550.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fonc.2022.994296 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1163.xml |
| 035 | |a (DE-627)NLM349004803 | ||
| 035 | |a (NLM)36387123 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chen, Dong |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Three-dimensional ultrasound integrating nomogram and the blood flow image for prostate cancer diagnosis and biopsy |b A retrospective study |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 18.11.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2022 Chen, Niu, Chen, Liu, Guo, Yao, Li, Luo, Li and Tang. | ||
| 520 | |a Backgrounds: Prostate cancer (PCa) is the second most common male cancer in the world and based on its high prevalence and overwhelming effect on patients, more precise diagnostic and therapeutic methods are essential research topics. As such, this study aims to evaluate the value of three-dimensional transrectal ultrasound (3D-TRUS) in the detection, diagnosis and biopsy of PCa, and to provide a basis for clinical practice of PCa | ||
| 520 | |a Methods: Retrospective analysis and comparison of a total of 401 male patients who underwent prostate TRUS in our hospital from 2019 to 2020 were conducted, with all patients having prostate biopsy. Nomogram was used to estimate the probability of different ultrasound signs in diagnosing prostate cancer. The ROC curve was used to estimate the screening and diagnosis rates of 3D-TRUS, MRI and TRUS for prostate cancer | ||
| 520 | |a Results: A total of 401 patients were randomly divided into two groups according to different methods of prostate ultrasonography, namely the TRUS group (251 patients) and the 3D-TRUS group (150 patients). Of these cases, 111 patients in 3D-TRUS group underwent MRI scan. The nomogram further determined the value of 3D-TRUS for prostate cancer. The ROC AUC of prostate cancer detected by TRUS, MRI and 3D-TRUS was 0.5580, 0.6216 and 0.6267 respectively. Biopsy complications were lower in 3D-TRUS group than TRUS group, which was statistically significant (P<0.005) | ||
| 520 | |a Conclusions: The accuracy of 3D-TRUS was higher in diagnosis and biopsy of prostate cancer. Meanwhile, the positive rate of biopsy could be improved under direct visualization of 3D-TRUS, and the complications could be decreased markedly. Therefore, 3D-TRUS was of high clinical value in diagnosis and biopsy of prostate cancer | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a biopsy | |
| 650 | 4 | |a diagnosis | |
| 650 | 4 | |a prostate cancer | |
| 650 | 4 | |a three-dimensional transrectal ultrasound | |
| 650 | 4 | |a transrectal ultrasound | |
| 700 | 1 | |a Niu, Yingjie |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Haitao |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Dequan |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Rong |e verfasserin |4 aut | |
| 700 | 1 | |a Yao, Nan |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Zhiyao |e verfasserin |4 aut | |
| 700 | 1 | |a Luo, Xiaomao |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Hongyang |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Shicong |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in oncology |d 2011 |g 12(2022) vom: 22., Seite 994296 |w (DE-627)NLM218189583 |x 2234-943X |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2022 |g day:22 |g pages:994296 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fonc.2022.994296 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2022 |b 22 |h 994296 | ||